BioNTech (NASDAQ:BNTX) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of BioNTech (NASDAQ:BNTX) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other brokerages also recently commented on BNTX. UBS Group cut their price objective on shares of BioNTech from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday. Citigroup reduced their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday, September 16th. Finally, Bank of America reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $123.60.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $87.51 on Friday. The business has a fifty day moving average price of $94.66 and a 200-day moving average price of $96.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.55 and a quick ratio of 7.80. The company has a market capitalization of $22.13 billion, a PE ratio of -12.78 and a beta of 1.28. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00.

Insider Activity

In related news, CEO Ugur Sahin sold 72,000 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the sale, the chief executive officer directly owned 108,209 shares of the company’s stock, valued at $10,521,161.07. This trade represents a 39.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 807,209 shares of company stock worth $79,246,837 over the last 90 days. Corporate insiders own 19.20% of the company’s stock.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its position in BioNTech by 31.5% during the third quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after buying an additional 118 shares during the period. ProShare Advisors LLC increased its holdings in BioNTech by 5.3% in the third quarter. ProShare Advisors LLC now owns 4,014 shares of the company’s stock valued at $395,000 after buying an additional 202 shares in the last quarter. AlphaCentric Advisors LLC raised its position in shares of BioNTech by 4.5% in the third quarter. AlphaCentric Advisors LLC now owns 6,547 shares of the company’s stock worth $644,000 after acquiring an additional 281 shares during the period. Parallel Advisors LLC raised its position in shares of BioNTech by 50.3% in the third quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock worth $83,000 after acquiring an additional 282 shares during the period. Finally, SBI Securities Co. Ltd. raised its position in shares of BioNTech by 5.5% in the third quarter. SBI Securities Co. Ltd. now owns 6,863 shares of the company’s stock worth $675,000 after acquiring an additional 358 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally.